XBiotech's vilamakitug meets primary efficacy goal in Phase II colorectal cancer trial
XBIT•XBiotech said vilamakitug met the prespecified primary efficacy criterion in the Phase II TASKIN trial for refractory metastatic colorectal cancer; an exploratory analysis found a statistically significant survival benefit in patients with right-sided tumors.
1. Trial results
XBiotech announced positive final TASKIN results for vilamakitug, which was evaluated in addition to standard treatment. The company said the findings support focusing on right-sided disease as vilamakitug advances toward registrational clinical development.
